Compare Cenovus Energy Inc (CVE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Cenovus Energy Inc trades at $31.38 (market cap $56.66B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.3× Cenovus Energy Inc's market cap, and Cenovus Energy Inc pays a 2.03% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CVE | VRTX | |
|---|---|---|
Market Cap | $56.66B | $128.16B |
Volume | 7,667,753 | 806,603 |
Sector | Energy | Health |
52-Week High | $33.92 | $557.96 |
52-Week Low | $15.85 | $407.37 |
Typical Hold Time | 46 Days | 120 Days |
Enterprise Value | $62.61B | $122.29B |
Dividend Yield | 2.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $30.63, down 1.95% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 12.14, EV/EBITDA of 6.03, and robust profitability metrics including 20.96% ROE. Recent analyst coverage shows 40.74% buy ratings, while technical indicators point to support near $30 with resistance at $31-32 levels. Cash flow trends indicate operational strength with $8.23B from operations in 2025.
CVE presents a mixed outlook with attractive valuation metrics and strong profitability offset by bearish technical signals. The company's projected 2026 revenue growth to $58B and net income of $6.7B suggests upside potential, though energy sector volatility and recent price weakness near key support levels warrant caution. Analyst consensus leans positive with limited sell-side coverage.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
